INTERPACE BIOSCIENCES, INC.
No SEC Form 4 filings for $IDXG in the last 30 days.
See all $IDXG insider activity →Interpace Biosciences (IDXG) anticipates Q3 2026 revenue of $10.1M–$10.4M, marking an 11%–14% quarterly increase and 15%–18% year-over-year growth, according to preliminary unaudited figures.
Interpace Biosciences expects Q3 2026 revenue of $10.1M-$10.4M, up 11%-14% from Q2 2026 and 15%-18% year-over-year. The company provides molecular diagnostic tests for thyroid evaluation. Actual results may differ due to ongoing review processes.
INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 20, 2026, the Company held its 2026 annual meeting of stockholders (the “ 2026 Annual Meeting ”). The following proposals were voted on and approved by the Company’s stockholders at the 2026 Annual Meeting
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IDXG (INTERPACE BIOSCIENCES, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent IDXG coverage spans earnings and corporate actions.
Guidance shows accelerating top‑line growth, which may lift the stock modestly.
Guidance suggests modest top‑line growth for a micro‑cap diagnostic firm.
The approved reverse split could reduce share count and increase price per share, affecting liquidity and valuation.
Thyroid-only transition is showing margin and EBITDA improvement, while revenue is roughly flat year over year.
AlphAI scores every news story that mentions IDXG with an AI model for sentiment and relevance, and aggregates insider trades from INTERPACE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Interpace Biosciences (IDXG) anticipates Q3 2026 revenue of $10.1M–$10.4M, marking an 11%–14% quarterly increase and 15%–18% year-over-year growth, according to preliminary unaudited figures.
1 min readInterpace Biosciences expects Q3 2026 revenue of $10.1M-$10.4M, up 11%-14% from Q2 2026 and 15%-18% year-over-year. The company provides molecular diagnostic tests for thyroid evaluation. Actual results may differ due to ongoing review processes.
1 min readINTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 20, 2026, the Company held its 2026 annual meeting of stockholders (the “ 2026 Annual Meeting ”). The following proposals were voted on and approved by the Company’s stockholders at the 2026 Annual Meeting
2 min readINTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%
6 min read
